XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.3
EPS Calculation
 9 Months Ended
Sep. 30, 2025
Earnings Per Share [Abstract]  
EPS Calculation EPS Calculation
 
The following table presents a reconciliation of the earnings/(loss) and shares used in calculating basic and diluted earnings/(loss) per share for the three and nine months ended September 30, 2025 and 2024:
 
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In Thousands, Except Per Share Amounts)2025202420252024
Basic Earnings/(Loss) per Share:
Net income/(loss) to common stockholders$48,104 $48,183 $122,464 $113,342 
Dividends declared on preferred stock(10,834)(8,219)(29,613)(24,656)
Dividends, dividend equivalents and undistributed earnings allocated to participating securities(188)(94)(593)(367)
Net income/(loss) attributable to common stockholders - basic$37,082 $39,870 $92,258 $88,319 
Basic weighted average common shares outstanding103,683 103,647 103,721 103,423 
Basic Earnings/(Loss) per Share$0.36 $0.38 $0.89 $0.85 
Diluted Earnings/(Loss) per Share:
Net income/(loss) to common stockholders - basic$37,082 $39,870 $92,258 $88,319 
Dividends, dividend equivalents and undistributed earnings allocated to participating securities— — — — 
Interest expense on Convertible Senior Notes— — — — 
Net income/(loss) attributable to common stockholders - diluted$37,082 $39,870 $92,258 $88,319 
Basic weighted average common shares outstanding103,683 103,647 103,721 103,423 
Unvested and vested restricted stock units2,063 2,744 1,871 2,508 
Effect of assumed conversion of Convertible Senior Notes to common shares— — — — 
Diluted weighted average common shares outstanding (1)
105,746 106,391 105,592 105,931 
Diluted Earnings/(Loss) per Share$0.35 $0.37 $0.87 $0.83 
(1)At September 30, 2025 and 2024, the Company had approximately 707,000 and 235,000 equity instruments outstanding that were excluded from the calculation of diluted EPS for the three and nine months ended September 30, 2025 and 2024, as they were determined to be anti-dilutive. These equity instruments reflect RSUs (based on current estimate of expected share settlement amount) with a weighted average grant date fair value of $10.38 and $11.25, respectively. These equity instruments may have a dilutive impact on future EPS.  
During the nine months ended September 30, 2024, the Convertible Senior Notes were determined to be anti-dilutive and were excluded from the calculation of diluted EPS under the “if-converted” method. Under this method, the periodic interest expense for dilutive notes is added back to the numerator and the weighted average number of shares that the notes are entitled to (if converted, regardless of whether the conversion option is in or out of the money) are included in the denominator for the purpose of calculating diluted EPS.